Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

PHASE2CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

August 30, 2022

Study Completion Date

September 25, 2024

Conditions
Mixed Dyslipidemia
Interventions
DRUG

ARO-ANG3

ARO-ANG3 Injection

DRUG

Placebo

Sterile Normal Saline (0.9% NaCl)

Trial Locations (24)

2148

Paratus Clinical Research, Blacktown

3010

Lakeland Clinical Trials - Rotorua, Rotorua

3200

Lakeland Clinical Trials - Waikato, Hamilton

4556

University of the Sunshine Coast Clinical Trials Centre, Sippy Downs

6009

Linear Clinical Research, Nedlands

8011

NZCR OpCo Ltd., Christchurch

10029

Icahn School of Medicine at Mount Sinai (ISMMS), New York

17011

Capital Area Research, LLC, Camp Hill

27408

Medication Management LLC, Greensboro

28557

Lucas Research, Inc., Morehead City

32127

Progressive Medical Research, Port Orange

33012

AGA Clinical Trials, Hialeah

33144

Global Research Solutions, Miami

43302

Marion Area Health Center, Marion

55455

University of Minnesota, Minneapolis

68114

Methodist Physicians Clinic Heart Consultants, Omaha

77030

Baylor College of Medicine, Houston

89121

Clinical Research of South Nevada, Las Vegas

90255

Velocity Clinical Research, Huntington Park

N6A 5A5

Lawson Health Research Institute, London

G7H 7K9

Centre d'Etudes Cliniques, Chicoutimi

G1G 3Z4

Recherche Clinique Sigma Inc, Québec

H7T2P5

Ctr de Recherche Clin de Laval, Québec

0626

Lakeland Clinical Trials - Waitemata, Birkenhead

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY